Alkermes (ALKS)
(Delayed Data from NSDQ)
$28.55 USD
+0.20 (0.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.56 +0.01 (0.04%) 5:56 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Brokerage Reports
0 items in cart
Alkermes plc [ALKS]
Reports for Purchase
Showing records 141 - 160 ( 297 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Is Evolution Enough? Vumerity Hits Primary Endpoint in EVOLVE-MS-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Vivitrol Settlement Settles Nerves After Mixed 2Q
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
The Evolution of Alkermes; Initiate With Neutral and $28 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Alkermes, Minerva; Assuming Coverage of Trevena
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D